Literature DB >> 21995627

The expression patterns and correlations of chibby, β-catenin, and DNA methyltransferase-1 and their clinicopathological significance in lung cancers.

Hong-Tao Xu1, Qing-Chang Li, Shun-Dong Dai, Xue-Mei Xie, D I Liu, En-Hua Wang.   

Abstract

Chibby is an inhibitor of the Wnt pathway. The expression and correlation of chibby in lung cancers is unclear. We considered that the expression pattern of chibby might be related to the expression of β-catenin and DNA methyltransferase-1 (DNMT1). We examined the expressions of chibby, β-catenin, and DNMT1 in 85 lung cancer tissues and corresponding normal lung tissues using immunohistochemistry. The nuclear expression rate of chibby was reduced in lung cancers (p < 0.001). Increased expression of DNMT1 was correlated with the differentiation (p = 0.034) and TNM stage (p = 0.048). The cytoplasmic expression of β-catenin was correlated with poor differentiation of lung cancers (p = 0.016). The cytoplasmic and membrane expression of chibby was positively correlated with the cytoplasmic (p = 0.025) and membrane (p = 0.029) expressions of β-catenin. The membrane expression of chibby was negatively correlated with the expression of DNMT1 (p = 0.006). Moreover, the expression of DNMT1 was correlated with the cytoplasmic expression of β-catenin (p < 0.001). The nuclear expression of chibby is reduced in lung cancers. Chibby may colocalize with β-catenin. β-Catenin and DNMT1 may be concurrently expressed and thereby promote the development of lung cancers.
© 2011 The Authors. APMIS © 2011 APMIS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21995627     DOI: 10.1111/j.1600-0463.2011.02799.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  A meta-analysis of abnormal β-catenin immunohistochemical expression as a prognostic factor in lung cancer: location is more important.

Authors:  Y Yang; J Shen; Jiaxi He; Jianxing He; G Jiang
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

2.  The high expression of TC1 (C8orf4) was correlated with the expression of β-catenin and cyclin D1 and the progression of squamous cell carcinomas of the tongue.

Authors:  Peng Zhang; Hong-Yi Cao; Lin-Lin Bai; Wei-Nan Li; Yuan Wang; Song-Yan Chen; Li Zhang; Lian-He Yang; Hong-Tao Xu; En-Hua Wang
Journal:  Tumour Biol       Date:  2015-04-14

3.  TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas.

Authors:  Hong-Tao Xu; Yang Liu; Shu-Li Liu; Yuan Miao; Qing-Chang Li; En-Hua Wang
Journal:  Virchows Arch       Date:  2013-02-02       Impact factor: 4.064

4.  Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.

Authors:  K Adam Morrow; Shamik Das; Erhong Meng; Mitchell E Menezes; Sarah K Bailey; Brandon J Metge; Donald J Buchsbaum; Rajeev S Samant; Lalita A Shevde
Journal:  Oncotarget       Date:  2016-04-05

5.  Downregulation of nuclear and cytoplasmic Chibby is associated with advanced cervical cancer.

Authors:  Ming-Chang Yang; Shang-Tao Chien; Tzu-Feng Yang; Shih-Yi Lin; Tai-Min Lee; Yi-Ren Hong
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

6.  Thyroid cancer 1 (C8orf4) shows high expression, no mutation and reduced methylation level in lung cancers, and its expression correlates with β-catenin and DNMT1 expression and poor prognosis.

Authors:  Yi-Wen Zheng; Li Zhang; Yuan Wang; Song-Yan Chen; Lei Lei; Na Tang; Da-Lei Yang; Lin-Lin Bai; Xiu-Peng Zhang; Gui-Yang Jiang; Lian-He Yang; Hong-Tao Xu; Qing-Chang Li; Xue-Shan Qiu; En-Hua Wang
Journal:  Oncotarget       Date:  2017-04-06

7.  Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma.

Authors:  Ming-Chao Tsai; Chao-Cheng Huang; Yu-Ching Wei; Ting-Ting Liu; Ming-Tsung Lin; Li-Na Yi; Pey-Ru Lin; Chih-Chi Wang; Tian-Huei Chu; Chang-Chun Hsiao; Tsung-Hui Hu; Ming-Hong Tai
Journal:  Int J Mol Sci       Date:  2020-03-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.